Menu Search
Equities

NANO MRNA Co Ltd

4571:DEU

NANO MRNA Co Ltd

Actions
  • Price (EUR)0.925
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-34.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.

  • Revenue in JPY (TTM)52.10m
  • Net income in JPY-821.00m
  • Incorporated1996
  • Employees18.00
  • Location
    NANO MRNA Co LtdOhnoya Kyobashi Bldg., 1-4-10, KyobashiMINATO-KU 105-6226JapanJPN
  • Phone+81 364324791
  • Fax+81 364324794
  • Websitehttps://www.nanomrna.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.